Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.72 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25209703 | 0.85 | MAOB (0.76) | KEAP1NFE2L2ABCG2MAOBLMNA | |
| SCHEMBL16485615 | 0.83 | KEAP1 (0.61) | KEAP1NFE2L2HRH3MAOBGAA | |
| SCHEMBL7487343 | 0.83 | KEAP1 (0.61) | KEAP1NFE2L2GAASMN1; SMN2KDM4E | |
| SCHEMBL17061257 | 0.83 | KEAP1 (0.61) | KEAP1NFE2L2HRH3MAOBGAA | |
| SCHEMBL7487334 | 0.83 | KEAP1 (0.61) | KEAP1NFE2L2GAASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL3424525 | 0.82 | KEAP1 (0.63) | KEAP1NFE2L2GAASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL3424522 | 0.82 | KEAP1 (0.63) | KEAP1NFE2L2GAASMN1; SMN2KDM4E | |
| SCHEMBL25212469 | 0.82 | KEAP1 (0.67) | KEAP1NFE2L2ABCG2MAOBSMN1; SMN2 | |
| SCHEMBL25189629 | 0.82 | KEAP1 (0.67) | KEAP1NFE2L2ABCG2MAOBSMN1; SMN2 | |
| SCHEMBL1958165 | 0.82 | NPC1 (0.66) | HRH3GAASMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | KEAP1 356/4885NFE2L2 554/4885HRH3 1465/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | KEAP1 210/4885NFE2L2 730/4885HRH3 577/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | KEAP1 210/4885NFE2L2 730/4885HRH3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.